Radiation Therapy Enhances Outcomes for NSCLC Patients Treated with Nivolumab - Takeaways - MDSpire

Radiation Therapy Enhances Outcomes for NSCLC Patients Treated with Nivolumab

  • By

  • Seray Saray

  • Berke Engin

  • Ahmet Kadıoğlu

  • Mustafa Akın

  • Hüseyin Kanmaz

  • Yakup İriağaç

  • February 26, 2026

  • 0 min

Share

  • 1

    Nivolumab, a PD-1 inhibitor, improves overall survival in advanced NSCLC compared to docetaxel, despite limited efficacy in some patients.

  • 2

    Radiation therapy (RT) can induce tumor-specific immune effects and may synergize with immune checkpoint inhibitors to enhance tumor control.

  • 3

    The study evaluated the impact of prior RT on progression-free survival and overall survival in advanced NSCLC patients treated with nivolumab.

  • 4

    Patients with oligoprogression during nivolumab treatment who received RT were included, highlighting the complexity of treatment responses.

  • 5

    Statistical analyses were performed to assess survival outcomes, with significant findings defined as p values less than 0.05.

Original Source(s)

Radiation Therapy Enhances Outcomes for NSCLC Patients Treated with Nivolumab

  • by Seray Saray, Berke Engin, Ahmet Kadıoğlu, Mustafa Akın, Hüseyin Kanmaz, Yakup İriağaç

  • February 26, 2026

Related Content

Machine learning–based prediction of mortality in lung cancer: Application of severity-adjustment method

Imaging features of lung cancer with cystic airspaces: clinical utility, challenges, and perspectives

Efficacy of IoT-based perioperative respiratory rehabilitation for lung resection: Protocol of a randomized controlled trial